Colfen 200 SP, 200 mg/g granules for use in drinking water for pigs

Main information

  • Trade name:
  • Colfen 200 SP, 200 mg/g granules for use in drinking water for pigs
  • Pharmaceutical form:
  • Granules for oral solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Colfen 200 SP, 200 mg/g granules for use in drinking water for pigs
    Portugal
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • florfenicol
  • Therapeutic area:
  • Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0456/001
  • Authorization date:
  • 29-05-2013
  • EU code:
  • UK/V/0456/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:June2013

AN:02085/2011

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

COLFEN200SP,200mg/ggranulesforuseindrinkingwaterforpigs.

(Denmark:ColfenSP)

(Spain:COLFEN200,200mg/ggranulesforuseindrinkingwaterforpigs)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachgcontains:

Activesubstance:

Florfenicol 200.0mg

Excipient(s):

Butylhydroxytoluene(E321) 1.0mg

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

Granulesforuseindrinkingwater.

Whitetocreamwaxygranules.

4. CLINICALPARTICULARS

4.1Targetspecies

Pigs

4.2Indicationsforuse,specifyingthetargetspecies

ForthetreatmentofswinerespiratorydiseaseassociatedwithPasteurella

multocidasusceptibletoflorfenicol.

4.3Contraindications

Donotadministertoboarsintendedforbreedingpurposes.

Donotadministerincasesofpreviousallergicreactionstoflorfenicoloranyofthe

excipients.

Donotuseinpigletslessthan6weeksold.

4.4Specialwarningsforeachtargetspecies

Ifthereisnosignificantimprovementafter3daysoftreatment,thediagnosis

shouldbereviewedandifnecessarythetreatmentshouldbechanged.

Issued:June2013

AN:02085/2011

Page2of6

4.5Specialprecautionsforuse

i)Specialprecautionsforuseinanimals

Theveterinarymedicinalproductshouldbeusedinconjunctionwith

susceptibilitytesting.Official,nationalandregionalantimicrobialpolicies

shouldbetakenintoaccountwhentheproductisused.

Inappropriateuseoftheveterinarymedicinalproductmayincreasethe

prevalenceofbacteriaresistanttoflorfenicol.

Treatmentshouldnotexceed5days.

ii)Specialprecautionsforthepersonadministeringtheveterinarymedicinal

producttoanimals

Avoidskinandeyecontactwithproduct.

Donoteat,drinkorsmokewhenhandlingtheproductormixingitwith

water.

Donotuseinknowncasesofsensitivitytopolyethyleneglycols.

Incaseofaccidentalspillageontoskinrinsewithwater.

4.6Adversereactions(frequencyandseriousness)

Diarrhoeahasbeenverycommonlyreported(upto30%ofanimals)and

inflammationoftheperianalarea(upto5%ofanimals)hasbeencommonly

reportedintreatedanimals.Theseeffectsaretransientandnormallyresolve

within5days.Rectalprolapsehasbeenuncommonlyreported.

Aslightreductioninfoodconsumptionmaybeobservedduringtreatment.

4.7Useduringpregnancy,lactationorlay

Thesafetyoftheproductduringpregnancyandlactationhasnotbeen

demonstrated.Useoftheproductduringpregnancyandlactationisthereforenot

recommended.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9Amount(s)tobeadministeredandadministrationroute

Oralrouteindrinkingwater.

10mgflorfenicol/kgbodyweightperdayindrinkingwaterfor5consecutivedays.

Thedailyamountofproducttobemixedwithdrinkingwatercanbecalculated

basedontheTotalBodyWeight(TBW)oftheherdtobetreatedwiththefollowing

formula:

Amountofproduct(in

grams)perday* = TotalBodyWeightoftheherd(TBW)inKg

20

*tobemixedwiththeestimatedtotalwaterconsumptionoftheherdin24hr

Issued:June2013

AN:02085/2011

Page3of6

Theexamplesofmedicateddrinkingwaterinthetablebelowarecalculatedby

applyingtheformulaandbyassumingthatpigsdrink8%or10%oftheir

bodyweight.

TBWofthe

herd(Kg) Product(g) Estimateddaily

water

consumption(L) Productgrams

per10litresof

water

Pigsdrinking

8%oftheir

bodyweight 500kg 25g 40L

6.25g/10L 1000kg 50g 80L

5000kg 250g 400L

Pigsdrinking

10%oftheir

bodyweight 500kg 25g 50L

5g/10L 1000kg 50g 100L

5000Kg 250g 500L

FORBULKTANK:Totreatpigsdrinking10%oftheirbodyweight,atthedoseof

10mg/kg:add5gproductper10Ldrinkingwaterinthebulktankandmix

thoroughlyuntilvisuallydissolved.

Forpigsdrinking8%oftheirbodyweight,atadoseof10mg/kg:add6,25gproduct

toevery10Ldrinkingwaterinthetankandmixthoroughlyuntilvisuallydissolved.

Anysolutionsforuseinaheadertankmustbelimitedtonomorethan2.5g/L.

Dissolutionmaytakeupto30minutesandsolutionsshouldbecheckedvisually

forcompletedissolution.

FORPROPORTIONER:Convenientproportionersettingsfortheuseof

florfenicolinthedrinkingwateris20%

Totreat5,000kgofpigs,drinking10%oftheirbodyweight,atthedoserateof

10mg/kg:

1. Filltheproportionerwith100Ldrinkingwater.

2. Add250gofproducttotheproportioner.

3. Mixthoroughlyuntilvisuallydissolved

4. Settheproportionerto20%.

5. Turnontheproportioner.

Inordertoensurerapiddissolution,solutionsshouldbepreparedinaccordance

withtheexamplesabove.Otherwise,solutionsshouldbevisuallyinspectedto

ensurethatdissolutioniscompletebeforetheproductisadministered.

Inordertoensurecorrectdosingandtopreventunderdosing,thebodyweightof

theherdshouldbecalculatedaspreciselyaspossibleandwaterconsumption

shouldbemonitored.Therequiredquantityofgranulesshouldbemeasuredby

suitablycalibratedweighingequipment.

Theuptakeofwaterdependsonseveralfactorsincludingtheage,theclinical

stateoftheanimalsandthelocalconditionssuchasambienttemperatureand

humidity.Thedailywaterconsumptioncanbeunderestimated(e.g.reducedto6%

ofbodyweight)inordertoensuretotalconsumptionofmedicatedwaterduringthe

day(freshdrinkingwatercanbemadeavailablefollowingtheconsumptionofthe

medicatedwater).Ifitisnotpossibletoobtainsufficientuptakeofmedicatedwater

animalsshouldbetreatedparenterally.Themaximumsolubilityoftheproduct

granulesis5g/Lat20°Cand2.5g/Lat9°C.

Medicateddrinkingwatershouldbereplacedevery24hours.

Issued:June2013

AN:02085/2011

Page4of6

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Afteradministrationat3timestherecommendeddoseareductioninfoodand

waterconsumption,togetherwithadecreaseinbodyweighthasbeenobserved.

Afteradministrationat3timesormoreoftherecommendeddose,depressionof

someanimalshavebeenobserved.

4.11Withdrawalperiod(s)

Meatandoffal:20days

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Amphenicols

ATCVetCode:QJ01BA90

5.1Pharmacodynamicproperties

Florfenicolisasynthetic,broad-spectrumantibioticinthephenicolgroupactive

againstmostGram-positiveandGram-negativeorganismsisolatedfromdomestic

animals.Florfenicolactsbyinhibitingproteinsynthesisattheribosomalleveland

maybeconsideredbacteriostatic.

However,bactericidalactivityhasbeendemonstratedinvitroagainststrainsof

Pasteurellamultocidaisolatedfrompigsandinvolvedinrespiratorydisease.

Amongclinicalisolatescollectedfromtherespiratorytractsofswinebetween

2008-2010intheEU,theobservedflorfenicolMIC

andMIC

were0.25 –1

µg/ml.ForP.multocidathefollowingbreakpointshavebeendeterminedfor

florfenicolinswinerespiratorydisease;susceptibe: ≤2µg/ml,intermediate:4

µg/mlandresistant: ≥8µg/ml(CLSIM31-A3,2008).

Acquiredresistancetoflorfenicolisassociatedwithseveralgenes,includingFloR

whichencodesaneffluxpump.Genesresponsibleforresistancearetransferable

bymobilegeneticelements.

5.2Pharmacokineticproperties

Followingadministrationofflorfenicolindrinkingwaterfor5consecutivedays,the

maximumplasmaconcentrationof3.92µg/mLoccurredatamedianof4hours.

Themeanplasmaconcentrationsremainedabove0.5µg/mLforthe5day

administrationperiod.Themeanterminalhalf-lifewas5.6hoursandmeanAUC

0-24

of44.7µg·h/mL.Themajorclearancemechanismisexcretioninurine.

5.3Environmentproperties

Florfenicoldegradesinpigmanureandinsoilandassuchwillnotpersistinthe

environment.

Issued:June2013

AN:02085/2011

Page5of6

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Butylhydroxytoluene(E321)

DisodiumEdetate

Macrogols(4000and400)

Maltodextrin

Polysorbate80

6.2Incompatibilities

Intheabsenceofcompatibilitystudiedthisveterinarymedicinalproductmustnot

bemixedwithotherveterinarymedicinalproducts.

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:4years

Shelflifeafterfirstopeningoftheimmediatepackaging:3months

Shelflifeafterdilutionorreconstitutionaccordingtodirections:24hours

6.4Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

Storeintheoriginalpackage.

6.5Natureandcompositionofimmediatepackaging

Polyester/aluminium/polythenebagscontaining0.5kg,1kgor5kgofgranules.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproduct

orwastematerialsderivedfromtheuseofsuchproducts,ifappropriate

Anyunusedveterinarymedicinalproductorwastematerialderivedfromsuch

veterinarymedicinalproductshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

ZoetisUKLtd

Floor,6StAndrewStreet

London

EC4A3AE

8. MARKETINGAUTHORISATIONNUMBER

Vm42058/4178

Issued:June2013

AN:02085/2011

Page6of6

9. DATEOFFIRSTAUTHORISATION

Date:June2013

10.DATEOFREVISIONOFTHETEXT

Date:June2013

Prohibitionofsale,supplyand/oruse:

Notapplicable.

APPROVED 24/06/13

13-12-2018

The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017

The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017

Published on: Wed, 12 Dec 2018 This report of the European Food Safety Authority and the European Centre for Disease Prevention and Control presents the results of zoonoses monitoring activities carried out in 2017 in 37 European countries (28 Member States (MS) and nine non-MS). Campylobacteriosis was the commonest reported zoonosis and its EU trend for confirmed human cases increasing since 2008 stabilised during 2013–2017. The decreasing EU trend for confirmed human salmonellosis cases since 2008 end...

Europe - EFSA - European Food Safety Authority Publications

20-11-2018

Peer review of the pesticide risk assessment of the active substance (EZ)‐1,3‐dichloropropene

Peer review of the pesticide risk assessment of the active substance (EZ)‐1,3‐dichloropropene

Published on: Mon, 19 Nov 2018 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State, Spain, for the pesticide active substance (EZ)‐1,3‐dichloropropene are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the representative uses of (EZ)‐1,3‐dichloropropene ...

Europe - EFSA - European Food Safety Authority Publications

10-11-2018

Outcome of the consultation with Member States and EFSA on the basic substance application for propolis extract (admissibility accepted when named water‐soluble extract of propolis) for use in plant protection as fungicide and bactericide

Outcome of the consultation with Member States and EFSA on the basic substance application for propolis extract (admissibility accepted when named water‐soluble extract of propolis) for use in plant protection as fungicide and bactericide

Published on: Fri, 09 Nov 2018 00:00:00 +0100 The European Food Safety Authority (EFSA) was asked by the European Commission to provide scientific assistance with respect to the evaluation of applications received by the European Commission concerning basic substances. In this context, EFSA's scientific views on the specific points raised during the commenting phase conducted with Member States and EFSA on the basic substance application for propolis extract are presented. The context of the evaluation ...

Europe - EFSA - European Food Safety Authority Publications

6-11-2018

Setting of import tolerances for haloxyfop‐P in linseed and rapeseed

Setting of import tolerances for haloxyfop‐P in linseed and rapeseed

Published on: Fri, 02 Nov 2018 00:00:00 +0100 In accordance with Article 6 of Regulation (EC) No 396/2005, the Australian Government Department of Agriculture and Water Resources submitted two requests to the competent national authority in Denmark to set import tolerances for the active substance haloxyfop‐P in linseed and rapeseed. The data submitted in support of the request were found to be sufficient to derive maximum residue level (MRL) proposals for linseed and rapeseed. Adequate analytical metho...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

26-9-2018

Modification of the existing maximum residue level for flonicamid in various crops

Modification of the existing maximum residue level for flonicamid in various crops

Published on: Tue, 25 Sep 2018 00:00:00 +0200 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Dienstleistungszentrum Ländlicher Raum submitted a request to the competent national authority in Germany to modify the existing maximum residue level (MRL) for the active substance flonicamid in radishes. Furthermore, in accordance with Article 6 of Regulation (EC) No 396/2005, the applicant ISK Biosciences Europe N.V. submitted a request to the competent national authority in the Ne...

Europe - EFSA - European Food Safety Authority Publications

20-9-2018

Getinge Issues Worldwide Voluntary Correction of Maquet/Getinge Cardiosave Intra-Aortic Balloon Pump (IABP) For Interruption and/or Inability to Start Therapy at Altitudes above 3,200 Feet/975 Meters

Getinge Issues Worldwide Voluntary Correction of Maquet/Getinge Cardiosave Intra-Aortic Balloon Pump (IABP) For Interruption and/or Inability to Start Therapy at Altitudes above 3,200 Feet/975 Meters

Getinge is voluntarily initiating a Worldwide recall involving a field correction of approximately 5,223 Maquet/Getinge Cardiosave Intra-Aortic Balloon Pumps (IABP) sold by Datascope Corp., for a potential interruption and/or inability to start therapy to the patient regarding the use of certain Intra-Aortic Balloons (IABs) prior to or during the use with Cardiosave IABP for users who are at altitudes above 3200 feet/975 meters. This condition could potentially lead to patient hemodynamic instability.

FDA - U.S. Food and Drug Administration

There are no news related to this product.